Is Immix Biopharma, Inc. (IMMX) a Buy, Sell, or Hold?
NASDAQ : IMMX
Immix Biopharma, Inc.
$8.32 USD
-$0.23 (-2.69%)
- Volume
- 1.59M
- Average Volume
- 1.76M
- Market Capitalization
- $452.62M
- P/E Ratio
- -9.04
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $12.14
- Year Low
- $1.94
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.76
Company Overview
NASDAQ
Ilya Rachman
Biotechnology
Healthcare
IMMX
21
US
USD
Liquidity Metrics
0.01
8.76
8.76
7.52
0.00
Sales & Valuation
-$
0.00
3.78
-13.81
-0.86
Profitability
-$0.89
-$29.44M
0.00%
0.00%
-73.23%
-36.51%
P/E Metrics
-9.04
0.36
0.36
Analyst Price Target & Rating
$17.00
$20.00
$14.00
2/5
4 Analysts
-51.06%
Financial Health Scores
21.86
2/9
$81.74M
$95.82M
$11.45M
-$34.95M
Key Metrics (TTM)
$374.41M
0.00
-10.83
8.76
-73.23%
-42.25%
-10.98%
-7.24%
-13203 days
Company Executives
| Name | Title |
|---|---|
| Gabriel Morris | President, CFO & Director |
| Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman |
| Vladimir Torchilin | Scientific Co-Founder |
| David Marks | Chief Medical Officer of Cell Therapy |
| Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development |
| Mel Davis-Pickett | Head of CMC Technical Development |
| Michael A. Grabow | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Immix Biopharma, Inc. (NASDAQ:IMMX) Stock
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating ... IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
2026-07-30 10:00:00
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-23 08:15:00
Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to learn more about how they might recover those losses.
Immix Biopharma Investigated by the Portnoy Law Firm
2026-07-21 13:51:00
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Immix " or the "Company") ( NASDAQ : IMMX ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
2026-07-20 17:33:00
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX) complied with federal securities laws. On July 20, 2026, Immix disclosed that it had terminated its Chief Medical Officer (“CMO”) following multiple news reports that the CMO had been using a false identity and was a recently captured fugitive. The price of the Company's stock dropped following this news.
2026-07-20 12:13:00
Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma") (NASDAQ: IMMX).
2026-07-20 11:47:00
BOSTON, July 20, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Immix Biopharma (Nasdaq: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to learn more about how they might recover those losses.
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
2026-06-24 13:01:07
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
2026-06-18 13:38:04
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
Frequently Asked Questions
-
What is the current Immix Biopharma, Inc. (IMMX) stock price?
-
Immix Biopharma, Inc.(NASDAQ:IMMX) stock price is $8.32 in the last trading session. During the trading session, IMMX stock reached the peak price of $12.14 while $1.94 was the lowest point it dropped to. The percentage change in IMMX stock occurred in the recent session was --2.69% while the dollar amount for the price change in IMMX stock was -$0.23.
-
IMMX's industry and sector of operation?
-
The NASDAQ listed IMMX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMMX?
-
Gabriel Morris | President, CFO & Director
Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman
Vladimir Torchilin | Scientific Co-Founder
David Marks | Chief Medical Officer of Cell Therapy
Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development -
How many employees does IMMX have?
-
Number of IMMX employees currently stands at 21. IMMX operates from 11400 West Olympic Boulevard, Los Angeles, CA 90064, US.
-
Link for IMMX official website?
-
Official Website of IMMX is: https://www.immixbio.com
-
How do I contact IMMX?
-
IMMX could be contacted at phone #310 651 8041 and can also be accessed through its website. IMMX operates from 11400 West Olympic Boulevard, Los Angeles, CA 90064, US.
-
How many shares of IMMX are traded daily?
-
The average number of IMMX shares traded daily for last 3 months was 1.76M.
-
What is the market cap of IMMX currently?
-
The market value of IMMX currently stands at $452.62M with its latest stock price at $8.32